FORT LAUDERDALE, Fla. — A senolytic therapy represents a novel approach to treating diabetic macular edema and wet age-related macular degeneration, according to a speaker at the Retina World Congress.
Raj Maturi, MD, presented data from a phase 1 study exploring the safety and efficacy of UBX1325 (Unity Biotechnology).
“This is an entirely new way of thinking about treating this disease,” he said. “What if we introduce a senolytic agent that actually eliminates the senescent cells and the source of these problems? It’s a chance for empty space to occur and,